Publications

by | April 1, 2011 | Uncategorized

Philippe Juvin MEP hosts a Lunch debate on Clinical Trials

On 22 March 2011 Philippe Juvin MEP (France, EPP) organised a lunch debate in the European Parliament in order to gather stakeholders for a discussion of the revision of the Clinical trials directive.

Speakers from the European Commission, the Pharmaceutical Industry, academia, the European Parliament and a patient’s organisation discussed the limitations of the current legislation (2001/20/CE) which first introduced a harmonised framework for clinical trials, and how it could be improved following its upcoming revision (likely to occur during the second quadrimester of 2012).

Dr Peter Leise MEP (Germany, EPP) and Mr Philippe Juvin (France, EPP) both support Commissioner Dalli in taking a ‘risks based approach’ based on more European harmonisation but maintaining strict privacy controls for patients. They would also like to see more clinical trials in order to get more medicines to market.

Paola Testori Coggi – Director General of DG SANCO was clear that the priorities for the European Commission are the safety, health and and rights of the patients together with the need for reliable data. She announced that the directive will only apply to medicinal products, not to non interventional studies. This provoked much discussion among participants, many of whom asserted that there are many other areas which could fall within the remit of the directive if its scope was extended.

The debate also heard from Professor Nicolas Danchin of the European Univerity Georges Pompidou Paris who spoke of his practical experience of conducting clinical trials in a University Hospital and Ms Kaisa Immonen-Charalambous of the European Patients Forum who encouraged more patient involvement in protocol design and undertaking of Clinical Trials.

Related EPHA articles

[->3494]

[->4062]

Get the EPHA Newsletter

The best of our activities, right in your inbox!